Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials

Anja Basan; Werner Kissling; Stefan Leucht

doi:10.1016/j.schres.2004.01.016

Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials

Schizophr Res. 2004 Sep 1;70(1):33-7. doi: 10.1016/j.schres.2004.01.016.

Authors

Anja Basan¹, Werner Kissling, Stefan Leucht

Affiliation

¹ Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München, Germany. anja.basan@lrz.tum.de

PMID: 15246461
DOI: 10.1016/j.schres.2004.01.016

Abstract

Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n = 379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review

MeSH terms

Anticonvulsants / pharmacology*
Anticonvulsants / therapeutic use*
Antipsychotic Agents / metabolism*
Antipsychotic Agents / therapeutic use*
Drug Synergism
Drug Therapy, Combination
Humans
Randomized Controlled Trials as Topic*
Schizophrenia / drug therapy*
Valproic Acid / pharmacology*
Valproic Acid / therapeutic use*

Substances

Anticonvulsants
Antipsychotic Agents
Valproic Acid